Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 18/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL499745 | 0.91 | REN (0.39) | RENCYP3A4SLC6A4SLC6A2 | |
| SCHEMBL498977 | 0.87 | REN (0.38) | RENCYP3A4SLC6A4SLC6A2 | |
| SCHEMBL4788345 | 0.87 | REN (0.38) | RENCYP3A4SLC6A4SLC6A2 | |
| SCHEMBL4756982 | 0.87 | REN (0.55) | RENCYP3A4 | |
| SCHEMBL3340010 | 0.87 | REN (0.55) | RENCYP3A4 | |
| SCHEMBL499549 | 0.87 | REN (0.55) | RENCYP3A4 | |
| SCHEMBL499077 | 0.85 | REN (0.55) | RENCYP3A4 | |
| SCHEMBL4789559 | 0.85 | REN (0.55) | RENCYP3A4 | |
| SCHEMBL499665 | 0.83 | REN (0.57) | RENCYP3A4 | |
| SCHEMBL4753688 | 0.83 | REN (0.57) | RENCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144825-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-06-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144825-A1 | Renin Inhibitors | ACE, REN, DNPEP | REN 2/4885CYP3A4 1848/4885SLC6A4 603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.